Morgantown, West Virginia Mylan Plant to Restart Production of Anti-Malaria Drug Hydroxychloroquine for Coronavirus Treatment

The Mylan plant in Morgantown, West Virginia willl restart production of hydroxychloroquine this week.

The drug was touted by researchers, doctors and President Trump in the treatment of the COVID-19 virus.

Generic Drug Company Teva in Israel is also mass-producing the drug to save lives.

The Dominion Post reported:

Mylan’s Morgantown plant is restarting production of an anti-malaria medication that is under study as a potential treatment for the COVID-19 virus.

The drug is hydroxychloroquine sulfate; the tablets are approved by the U.S. Food and Drug Administration for the treatment of malaria, lupus erythematosus and rheumatoid arthritis.

President Trump on Thursday touted its cousin, chloroquine, as a potential treatment and mistakenly said it has been FDA approved for COVID-19.

Mylan clarified, “Although the product is not currently approved for use in the treatment of COVID-19, it is listed by the World Health Organization as a drug under investigation for efficacy against the coronavirus.”

The drug had been in short supply earlier in March, according to news reports, but Mylan and another generic drug firm, Israel-based Teva, are both ramping up production.

You Might Like